These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24148813)

  • 1. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
    LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G
    Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
    Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
    Kitajima T; Mizote S; Bonifácio MJ; Umemura T; Yoneda K; Moser P; Soares-da-Silva P; Tanaka M
    Neuropharmacology; 2018 Dec; 143():282-288. PubMed ID: 30290160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
    Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
    Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
    Clin Pharmacokinet; 2013 Feb; 52(2):139-51. PubMed ID: 23248072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
    Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
    Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
    Müller T; Schlegel E; Zingler S; Thiede HM
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.